Skip to main content

Table 1 Liquid chromatography-tandem mass spectrometry (LC–MS/MS) assessment

From: Light and heavy chain deposition disease with focal amyloid deposition diagnosed with mass spectrometry: a case report

Description

emPAI

Immunoglobulin kappa constant OS=Homo sapiens OX=9606 GN=IGKC PE=1 SV=2

37.99

Apolipoprotein E OS=Homo sapiens OX=9606 GN=APOE PE=1 SV=1

12

Vitronectin OS=Homo sapiens OX=9606 GN=VTN PE=1 SV=1

1.72

Clusterin OS=Homo sapiens OX=9606 GN=CLU PE=1 SV=1

1.23

Immunoglobulin heavy constant alpha 1 OS=Homo sapiens OX=9606 GN=IGHA1 PE=1 SV=2

1.22

Serum amyloid P-component OS=Homo sapiens OX=9606 GN=APCS PE=1 SV=2

1.02

Apolipoprotein A-I OS=Homo sapiens OX=9606 GN=APOA1 PE=1 SV=1

0.97

Apolipoprotein A-IV OS=Homo sapiens OX=9606 GN=APOA4 PE=1 SV=3

0.22

Basement membrane-specific heparan sulphate proteoglycan core protein

OS=Homo sapiens OX=9606 GN=HSPG2 PE=1 SV=4

0.14

  1. LC–MS/MS revealed abundant kappa chains, minimal amounts of IgA heavy chains, and amyloid-associated proteins
  2. Abbreviation: emPAI Exponentially modified Protein Abundance Index